HopeStage
Back to all studies
CompletedNCT04814355

Celecoxib and brain inflammation in major depression

About this titleRead the official source — NCT04814355
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Stony BrookSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 1, 2018
Recruitment status
Completed
Enrollment listed in the registry
41
Sponsor
Stony Brook University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT04814355
Official title
Show the full official title

The Effect of Celecoxib on Neuroinflammation in MDD: PET Imaging of a Novel Treatment Target With [18F]FEPPA

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Stony Brook

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Stony Brook University, a university.

Did this study involve medication?

Yes. The study involved medication, including Celecoxib 400 mg.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies